Nontolerance to the opioid antagonism of naltrexone

Herbert D. Kleber, Thomas R. Kosten, Joseph Gaspari, Mark Topazian

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Controlled opiate challenges of naltrexone-pretreated human subjects have established that naltrexone is an effective opioid antagonist. However, these challenges have been conducted after relatively acute dosing with naltrexone, and tolerance to this antagonism after chronic treatment is possible. We therefore administered morphine challenges in a double-blind, placebo-controlled design to nine ex-addicts who had been taking naltrexone for a mean of 9.4 months. None of the ex-addicts experienced euphoria; instead, most of these blockaded ex-addicts had a dysphoric histaminelike response to the intravenous morphine. The only physiological change was a slight increase in heart rate. We conclude that tolerance does not develop to the opioid antagonist properties of naltrexone up to as long as 21 months of treatment.

Original languageEnglish (US)
Pages (from-to)66-72
Number of pages7
JournalBiological Psychiatry
Volume20
Issue number1
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Naltrexone
Opioid Analgesics
Narcotic Antagonists
Morphine
Opiate Alkaloids
Heart Rate
Placebos
Therapeutics

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Nontolerance to the opioid antagonism of naltrexone. / Kleber, Herbert D.; Kosten, Thomas R.; Gaspari, Joseph; Topazian, Mark.

In: Biological Psychiatry, Vol. 20, No. 1, 01.01.1985, p. 66-72.

Research output: Contribution to journalArticle

Kleber, Herbert D. ; Kosten, Thomas R. ; Gaspari, Joseph ; Topazian, Mark. / Nontolerance to the opioid antagonism of naltrexone. In: Biological Psychiatry. 1985 ; Vol. 20, No. 1. pp. 66-72.
@article{30ef4bbf9a04448ca31bae2445375a63,
title = "Nontolerance to the opioid antagonism of naltrexone",
abstract = "Controlled opiate challenges of naltrexone-pretreated human subjects have established that naltrexone is an effective opioid antagonist. However, these challenges have been conducted after relatively acute dosing with naltrexone, and tolerance to this antagonism after chronic treatment is possible. We therefore administered morphine challenges in a double-blind, placebo-controlled design to nine ex-addicts who had been taking naltrexone for a mean of 9.4 months. None of the ex-addicts experienced euphoria; instead, most of these blockaded ex-addicts had a dysphoric histaminelike response to the intravenous morphine. The only physiological change was a slight increase in heart rate. We conclude that tolerance does not develop to the opioid antagonist properties of naltrexone up to as long as 21 months of treatment.",
author = "Kleber, {Herbert D.} and Kosten, {Thomas R.} and Joseph Gaspari and Mark Topazian",
year = "1985",
month = "1",
day = "1",
doi = "10.1016/0006-3223(85)90136-2",
language = "English (US)",
volume = "20",
pages = "66--72",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Nontolerance to the opioid antagonism of naltrexone

AU - Kleber, Herbert D.

AU - Kosten, Thomas R.

AU - Gaspari, Joseph

AU - Topazian, Mark

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Controlled opiate challenges of naltrexone-pretreated human subjects have established that naltrexone is an effective opioid antagonist. However, these challenges have been conducted after relatively acute dosing with naltrexone, and tolerance to this antagonism after chronic treatment is possible. We therefore administered morphine challenges in a double-blind, placebo-controlled design to nine ex-addicts who had been taking naltrexone for a mean of 9.4 months. None of the ex-addicts experienced euphoria; instead, most of these blockaded ex-addicts had a dysphoric histaminelike response to the intravenous morphine. The only physiological change was a slight increase in heart rate. We conclude that tolerance does not develop to the opioid antagonist properties of naltrexone up to as long as 21 months of treatment.

AB - Controlled opiate challenges of naltrexone-pretreated human subjects have established that naltrexone is an effective opioid antagonist. However, these challenges have been conducted after relatively acute dosing with naltrexone, and tolerance to this antagonism after chronic treatment is possible. We therefore administered morphine challenges in a double-blind, placebo-controlled design to nine ex-addicts who had been taking naltrexone for a mean of 9.4 months. None of the ex-addicts experienced euphoria; instead, most of these blockaded ex-addicts had a dysphoric histaminelike response to the intravenous morphine. The only physiological change was a slight increase in heart rate. We conclude that tolerance does not develop to the opioid antagonist properties of naltrexone up to as long as 21 months of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0022191033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022191033&partnerID=8YFLogxK

U2 - 10.1016/0006-3223(85)90136-2

DO - 10.1016/0006-3223(85)90136-2

M3 - Article

C2 - 2981129

AN - SCOPUS:0022191033

VL - 20

SP - 66

EP - 72

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 1

ER -